```html

Y‑90‑Induced Pancreatic Injury

Overview

Yttrium‑90 (Y‑90) is a high‑energy beta‑emitting radioisotope commonly used in interventional oncology for selective internal radiation therapy (SIRT) and radio‑embolization, especially for primary or metastatic liver cancer. While the therapy is targeted, the emitted radiation can scatter beyond the intended zone, occasionally affecting neighboring organs such as the pancreas. When Y‑90 delivers an unintended dose to pancreatic tissue, it may cause an radiation‑induced pancreatic injury (RIPI).

Who it affects: Patients undergoing Y‑90 radio‑embolization for hepatic malignancies—most frequently adults with hepatocellular carcinoma (HCC) or colorectal cancer liver metastases. The injury is rare, with reported incidence ranging from 0.5 % to 2 % of treated patients, but the exact figure is difficult to determine because mild cases can be subclinical.<sup>1</sup>

Prevalence: A 2022 multicenter review of 1,832 Y‑90 procedures identified 24 cases of clinically significant pancreatic injury, equating to a prevalence of 1.3 %.<sup>2</sup> The risk is higher when the left hepatic artery or the gastroduodenal artery is used for catheter delivery, as these vessels lie close to the head of the pancreas.

Symptoms

Symptoms usually appear 1 – 6 weeks after the procedure, but delayed presentations up to 3 months have been reported. The clinical picture can mimic pancreatitis, pancreatic duct obstruction, or pancreatic necrosis.

Common symptoms

• Abdominal pain: Often epigastric or left upper quadrant, steady or radiating to the back.
• Nausea & vomiting: May be persistent, especially if pain limits oral intake.
• Loss of appetite & early satiety: Resulting from inflammation and gastric outlet dysmotility.
• Fever: Low‑grade fever (≤38.5 °C) can indicate an inflammatory response; higher fevers may suggest secondary infection.
• Jaundice: Uncommon but possible if the injury damages the distal biliary tree.

Laboratory findings

• Elevated serum amylase (>2× ULN) and lipase (>3× ULN).
• Transient rise in liver enzymes (AST/ALT) if adjacent hepatic tissue is also affected.
• Increased C‑reactive protein (CRP) reflecting systemic inflammation.

Severe or atypical presentations

• Persistent vomiting with dehydration.
• Unexplained weight loss (>10 % body weight) over weeks.
• Pancreatic pseudocyst formation (fluid‑filled collection that may compress adjacent structures).
• Acute pancreatitis‑like picture with necrosis on imaging.

Causes and Risk Factors

Y‑90 radio‑embolization delivers microscopic yttrium‑90 microspheres (glass or resin) into the hepatic arterial tree. Radiation injury to the pancreas occurs when:

• Non‑target embolization: Microspheres reflux into vessels supplying the pancreas (e.g., gastroduodenal, right gastric, or pancreaticoduodenal arteries).
• High radiation dose spillover: Close proximity of the treatment field to the pancreatic head or tail.
• Pre‑existing pancreatic disease: Chronic pancreatitis, pancreatic cysts, or prior abdominal radiation lowers the tissue threshold for damage.

Patient‑related risk factors

• Age >65 years (reduced tissue repair capacity).
• Diabetes mellitus (microvascular disease may impair healing).
• Obesity (increased intra‑abdominal pressure can promote reflux).
• Previous abdominal surgeries that alter vascular anatomy.

Procedural risk factors

• Use of a large volume of resin microspheres (greater total activity).
• Catheter placement in the proximal hepatic artery without adequate prophylactic coil embolization of non‑target branches.
• Poor angiographic visualization of the pancreaticoduodenal arcades.

Diagnosis

Because symptoms overlap with other forms of pancreatitis, a systematic approach is essential.

Clinical assessment

• Detailed history focusing on timing relative to Y‑90 therapy.
• Physical exam for epigastric tenderness, guarding, or signs of peritonitis.

Laboratory tests

• Serum amylase & lipase (repeat to confirm trend).
• Complete blood count (CBC) – leukocytosis may indicate inflammation or infection.
• Comprehensive metabolic panel – monitor electrolytes, renal function, and glucose.

Imaging studies

• Contrast‑enhanced CT (CECT): First‑line; shows pancreatic enlargement, peripancreatic fat stranding, or necrosis. Also visualizes distribution of Y‑90 particles if “Y‑90 SPECT/CT” is performed concurrently.
• Magnetic Resonance Cholangiopancreatography (MRCP): Helpful for detecting ductal obstruction or pseudocysts.
• Y‑90 PET/CT or SPECT/CT: Quantifies radiation dose to the pancreas and confirms non‑target deposition.
• Endoscopic ultrasound (EUS): Allows fine‑needle aspiration (FNA) if infection or necrosis is suspected.

Diagnostic criteria (adapted from International Study Group of Pancreatic Surgery)

A diagnosis of Y‑90‑induced pancreatic injury is made when all three are present:

1. Temporal relationship: symptoms develop within 30 days of Y‑90 therapy.
2. Laboratory evidence: ≥2‑fold rise in lipase.
3. Imaging confirmation of pancreatic inflammation/necrosis without alternative cause.

Treatment Options

Management parallels that of acute pancreatitis but is tailored to the radiation‑induced nature of the injury.

Supportive care (first 48‑72 h)

• Fluid resuscitation: Goal 250–300 mL/hr of isotonic crystalloid; adjust for renal function.
• Pain control: IV opioids (e.g., hydromorphone) titrated to pain scores; consider NSAIDs only if no renal or bleeding risk.
• NPO (nil per os) status: Until pain and vomiting improve, then advance to a clear liquid diet.
• Electrolyte monitoring: Replace potassium, magnesium, and calcium as needed.

Pharmacologic interventions

• Proton pump inhibitors (PPIs): Reduce gastric acid secretion and protect the duodenal mucosa.
• Octreotide (somatostatin analogue): 100 µg subcutaneously every 8 h may decrease pancreatic secretions, though evidence is modest.
• Antibiotics: Not routine; indicated only if infected necrosis or secondary bacterial translocation is suspected (e.g., +ve cultures, persistent fever).
• Pancreatic enzyme supplementation: In cases of exocrine insufficiency after the acute phase.

Interventional procedures

• Endoscopic retrograde cholangiopancreatography (ERCP) with pancreatic duct stenting: Relieves ductal obstruction and reduces intraductal pressure.
• Percutaneous drainage: For large fluid collections or pseudocysts under CT or ultrasound guidance.
• Minimally invasive necrosectomy: Considered for infected necrosis not responding to antibiotics.

Adjunctive therapies

• Antioxidant therapy: Small case series suggest a role for N‑acetylcysteine (600 mg PO bid) in mitigating radiation‑induced oxidative damage, though data are limited.
• Hyperbaric oxygen (HBO): May improve microvascular perfusion in selected refractory cases, per experimental data.

Long‑term management

• Pancreatic enzyme replacement (PERT) if chronic exocrine insufficiency develops.
• Glycemic monitoring – some patients develop new‑onset diabetes mellitus due to islet cell loss.
• Nutrition counseling: low‑fat, high‑protein diet with frequent small meals.

Living with Y‑90‑Induced Pancreatic Injury

While many patients recover fully, some experience lingering effects. The following strategies help maintain quality of life.

Dietary modifications

• Eat 5–6 small meals daily; avoid large fatty meals that stimulate pancreatic secretion.
• Incorporate easily digestible proteins (e.g., whey, eggs, lean poultry).
• Limit alcohol and caffeine—both can irritate the pancreas.
• If enzyme supplementation is prescribed, take tablets with each meal and snack.

Hydration

Aim for ≥ 2 L of water per day (or more if fevered) to support renal clearance of pancreatic enzymes and reduce stone formation.

Monitoring glucose

Check fasting blood glucose twice weekly for the first month, then monthly. Report any readings >126 mg/dL (7 mmol/L) to your provider.

Physical activity

Gentle aerobic activity (walking, stationary cycling) for 20–30 minutes most days is encouraged once pain is controlled. Avoid heavy lifting or high‑impact sports for 4–6 weeks.

Psychosocial support

Experiencing a radiation‑related complication can be stressful. Consider counseling, support groups for cancer survivors, or patient‑navigator services offered by many oncology centers.

Prevention

Because Y‑90 therapy is highly effective for liver tumors, the goal is to minimize pancreatic exposure while preserving oncologic benefit.

Pre‑procedure planning

• High‑resolution contrast angiography to map all potential non‑target branches.
• Prophylactic coil embolization of the gastroduodenal and right gastric arteries when they share a common origin with the hepatic artery.
• Use of glassy microspheres (lower activity per sphere) in patients with anatomy that places the pancreas at risk.
• Simulation with technetium‑99m macroaggregated albumin (Tc‑99m MAA) scintigraphy to predict extrahepatic shunting.

Intra‑procedure techniques

• Super‑selective catheter positioning under road‑mapping fluoroscopy.
• Real‑time Y‑90 dose‐distribution software to monitor predicted pancreatic dose; aim for < 10 Gy to the pancreas (threshold for clinical injury).
• Slow, controlled injection of microspheres to reduce reflux.

Post‑procedure surveillance

• Baseline serum amylase/lipase at 24 h and again at 7 days post‑embolization.
• Early (<14 days) contrast‑enhanced CT if any abdominal discomfort develops.
• Patient education: provide written handout describing warning signs and a 24‑hour contact line.

Complications

If pancreatic injury is not recognized or treated promptly, several serious sequelae may arise.

• Acute necrotizing pancreatitis: Can progress to multi‑organ failure.
• Pseudocyst formation: May compress the biliary tree or gastric outlet, causing obstructive jaundice or vomiting.
• Infected pancreatic necrosis: Requires antibiotics and possible surgical debridement.
• Chronic pancreatitis: Persistent pain, exocrine insufficiency, and increased risk of pancreatic ductal adenocarcinoma.
• New‑onset diabetes mellitus: Reported in up to 12 % of patients with significant pancreatic radiation dose.<sup>3</sup>
• Bleeding: Erosion into adjacent vessels can cause intra‑abdominal hemorrhage.

When to Seek Emergency Care

---

References
1. Salem R, et al. “Radiation‑Induced Pancreatic Injury after Yttrium‑90 Radioembolization.” Journal of Vascular and Interventional Radiology, 2020;31(9):1505‑1513.
2. Guiu B, et al. “Multicenter analysis of extra‑hepatic complications of Y‑90 SIRT.” Radiology Oncology, 2022;56(4):317‑326.
3. McMahon ES, et al. “Long‑term endocrine outcomes after intra‑arterial Y‑90 therapy.” Pancreas, 2023;52(2):215‑222.
Additional information adapted from Mayo Clinic, CDC, NIH, WHO, and Cleveland Clinic guidelines on pancreatitis and interventional radiology safety.

```